



PharmaPlus Consultancy BV

PharmaPlus Deal Financials - Research Institutes

Free sample

Source: PharmaPlus Consultancy BV

Disclaimer

This report has been produced exclusively for the person or organization mentioned on the frontpage of this report. No part of this report may be copied, reproduced, transmitted or resold (or provided free of charge) in any form or by any means to any third party that is not an authorised user. The information in this report has been collected and validated on a best-effort-basis. However, PharmaPlus Consultancy does not guarantee the completeness or accuracy of any profile published in the report. PharmaPlus Consultancy cannot be held liable for any information available or missing from the report.

PharmaPlus Consultancy BV

Licensor	Seattle's Children's Research Institute
Licensee	Juno Therapeutics
Year of last IPO-filing	2014
Year of deal closure	2014
Currency	USD

COMPOUND DETAILS

Compound details	Regulated transgene expression and CAR constructs, including bispecific CARs and customized spacer regions and their therapeutic, prophylactic and diagnostic use in immunotherapy
------------------	--

DEAL TERMS (mln)

Upfront	amount	0.2
Milestones total	amount remarks	16.3 per product
Milestones regulatory	amount remarks	13.3 per product
Milestones sales	amount remarks	3 per product
Annual maintenance fee	amount remarks	0.2 0.05 1st 5 years; thereafter 0.2
Royalties % on net sales	amount remarks	N/A Low single-digit
Sublicensing %	amount remarks	N/A Up to aggregate 15 million
Equity	amount	0
Territory		worldwide
Overall remarks		Research agreement less than 1.5 million over 5 years with exclusive option; in some circumstances option exercise fees of 0.1 million for improvements; potentially additional milestones and royalties

PharmaPlus Consultancy BV

PharmaPlus Consultancy BV is a strategic consulting and biopharmaceutical business development company. We work with biotech and pharmaceutical companies and non-profit research organizations. We focus on products and technologies with strong innovation and intellectual property.

We facilitate early stage (preclinical-clinical phase II) licensing deals based on strategic technology analysis and consulting, business development and deal negotiation. We uniquely combine our full consultancy services with technology scouting, university licensing deal reports and two distinctive online licensing databases.

Our approach balances new and innovative as well as traditional solutions to your key objectives. We offer our services on a worldwide basis and work with an international network of partners. We are totally committed and work based on a review of your needs, goals and challenges.

Our expertise

- Technology screening
- Licensing opportunity identification
- Patent portfolio analysis
- In-licensing & out-licensing
- Partnering strategy
- Non-confidential teasers
- Partner identification
- Licensing negotiations
- Unpublished Pharma Patent Applications database - early stage partnering database
- Biotechgate Licensing Deals database - online licensing deal financials database
- University Licensing Deals database extracts

Interested to learn more? We invite you to visit our website www.pharmaplus.nl